FIELD: medicine, pharmaceutics.
SUBSTANCE: given invention concerns β-amino acids, namely to way of linkage with an alpha-2-delta-subunit of the calcium channel, including introduction of therapeutically effective quantity of bond of the formula I 
to mammal. These bonds and their pharmaceutically comprehensible salts are useful and can be used for treatment of diseases, such as an epilepsy, postherpetic neuralgia, chronic headache, pain in the lower part of a back, pain as a result of surgical intervention, damages of cartilages.
EFFECT: obtaining of bonds for treatment of diseases, such as epilepsy, postherpetic neuralgia, chronic headache, pain in the lower part of a back, pain as a result of surgical intervention, damages of cartilages.
5 cl, 17 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOMODULATORY AZALIDES BASED ON UREA | 2021 |
|
RU2811591C1 |
| DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| COMBINATIONS OF ALPHA-2-DELTA-LIGAND WITH SELECTIVE CYCLOIXYGENASE-2 INHIBITOR | 2003 |
|
RU2286151C2 |
| MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
| SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
